Home / Insights Enterprise Newsletter / Insights Newsletter: Flu Vaccines in 2021-2022, Acquisition of Bula Intelligence, New CE for October, and More!

Emphasize the Importance of Flu Vaccination in 2021-2022

Evaluate Tocilizumab Alternatives for COVID-19

  • Pain Point: Tocilizumab shortages are leading to questions about which medication to use in its place for COVID-19 treatment in hospitalized patients.
  • Solution: Our article and chart, Treatments of Interest for COVID-19, review the available evidence and emergency use authorizations (EUA) for the possible alternatives: baricitinib, sarilumab, and tofacitinib. We provide recommendations on when to consider these medications as tocilizumab alternatives and when to avoid them.

This month’s Insights also announces our recent acquisition of Bula Intelligence–allowing us to expand our regulatory and legislative coverage for U.S. pharmacies.

And don’t miss out on our most popular charts, as well as the latest COVID-19 resources that are available. You’ll also get details on freshly released CE/CME courses, and can’t-miss webinars.

Need timely, concise updates for your pharmacy teams on topics like preventing errors with risky med labeling and packaging, COVID-19 treatments, and more? Learn more about Enterprise solutions from TRC >>

Subscribe to Insights Newsletter

Want updates like these delivered straight into your inbox? Subscribe to the Insights monthly newsletter today. Click below, then scroll  to “TRC News and Special Offers” and check the “Insights Enterprise Newsletter” box.